DDInter1266 DDInter1576
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Naproxen {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Naproxen {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Naproxen {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Naproxen (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may lead to a major life threatening interaction when taken with Regorafenib
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Flurbiprofen may lead to a major life threatening interaction when taken with Regorafenib
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Naproxen (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Naproxen (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Naproxen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib